Pulmonx Debt to Equity Ratio 2019-2023 | LUNG
Current and historical debt to equity ratio values for Pulmonx (LUNG) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Pulmonx debt/equity for the three months ending December 31, 2023 was 0.30.
| Pulmonx Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2023-12-31 | $0.06B | $0.12B | 0.50 |
| 2023-09-30 | $0.06B | $0.13B | 0.47 |
| 2023-06-30 | $0.06B | $0.13B | 0.44 |
| 2023-03-31 | $0.06B | $0.14B | 0.40 |
| 2022-12-31 | $0.04B | $0.15B | 0.26 |
| 2022-09-30 | $0.04B | $0.16B | 0.24 |
| 2022-06-30 | $0.04B | $0.17B | 0.24 |
| 2022-03-31 | $0.04B | $0.18B | 0.22 |
| 2021-12-31 | $0.04B | $0.19B | 0.22 |
| 2021-09-30 | $0.04B | $0.20B | 0.22 |
| 2021-06-30 | $0.04B | $0.21B | 0.19 |
| 2021-03-31 | $0.04B | $0.22B | 0.18 |
| 2020-12-31 | $0.04B | $0.23B | 0.17 |
| 2020-09-30 | $0.28B | $-0.21B | -1.34 |
| 2020-06-30 | $0.00B | $0.00B | 0.00 |
| 2020-03-31 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.00B | 0.00 | |
| 2019-09-30 | $0.00B | $0.00B | 0.00 |
| 2018-12-31 | $0.04B | $-0.03B | -1.56 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.281B | $0.069B |
| Pulmonx Corporation is a medical technology company. It designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. Pulmonx Corporation is based in Redwood City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GE HealthCare Technologies (GEHC) | United States | $39.221B | 21.82 |
| Inspire Medical Systems (INSP) | United States | $6.999B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $3.463B | 0.00 |
| Axonics (AXNX) | United States | $3.394B | 0.00 |
| 10x Genomics (TXG) | United States | $3.206B | 0.00 |
| Enovis (ENOV) | United States | $3.022B | 22.96 |
| Azenta (AZTA) | United States | $2.872B | 234.09 |
| Olink Holding AB (publ) (OLK) | Sweden | $2.869B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $2.629B | 0.00 |
| Privia Health (PRVA) | United States | $2.135B | 94.68 |
| Schrodinger (SDGR) | United States | $1.688B | 0.00 |
| Omnicell (OMCL) | United States | $1.246B | 30.48 |
| Phreesia (PHR) | United States | $1.154B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.793B | 0.00 |
| Standard BioTools (LAB) | United States | $0.685B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.599B | 0.00 |
| Talkspace (TALK) | United States | $0.520B | 0.00 |
| Clover Health Investments (CLOV) | United States | $0.332B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.328B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.323B | 0.00 |
| American Well (AMWL) | United States | $0.156B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.152B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.147B | 0.00 |
| Augmedix (AUGX) | United States | $0.136B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.131B | 0.00 |
| Outset Medical (OM) | United States | $0.123B | 0.00 |
| TruBridge (TBRG) | United States | $0.115B | 4.91 |
| 111 (YI) | China | $0.084B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.077B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.070B | 0.00 |
| HeartBeam (BEAT) | United States | $0.052B | 0.00 |
| Zepp Health (ZEPP) | China | $0.052B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.045B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.031B | 0.00 |
| Movano (MOVE) | United States | $0.027B | 0.00 |
| Cue Health (HLTH) | United States | $0.023B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.022B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.020B | 0.00 |
| Akili (AKLI) | United States | $0.019B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.019B | 0.00 |
| CareCloud (CCLD) | United States | $0.017B | 0.00 |
| ETAO (ETAO) | United States | $0.015B | 0.00 |
| Centogene (CNTG) | Germany | $0.013B | 0.00 |
| Biotricity (BTCY) | United States | $0.012B | 0.00 |
| Transgenomic (PRPO) | United States | $0.009B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.007B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| Syra Health (SYRA) | United States | $0.006B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Zhongchao (ZCMD) | China | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |